Načítá se...
Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint
Blockade of the immunoinhibitory PD-1/PD-L1 pathway using monoclonal antibodies has shown impressive results with durable clinical antitumor responses. Anti-PD-1 and anti-PD-L1 antibodies have now been approved for the treatment of a number of tumor types whereas the development of small molecules t...
Uloženo v:
| Vydáno v: | Angew Chem Int Ed Engl |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6400216/ https://ncbi.nlm.nih.gov/pubmed/28881104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.201707707 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|